The regulatory sweep watches drug approvals and recalls, and found nothing new today that bears on imaging practice — which is the usual state for radiology, because it does not cover the things that actually change imaging: appropriateness criteria, dose and contrast standards, and society protocols published as web pages.
The most relevant recent guidance is the American College of Radiology's 2026 update to its Appropriateness Criteria for myelopathy. It sets out evidence-based first-line imaging for acute, chronic and vascular cord dysfunction, developed with GRADE-adapted methodology and expert panel review.
Use it to standardise the initial study for suspected myelopathy rather than defaulting by habit, and to justify the choice when a request is ambiguous.
- No new FDA drug or device action affecting imaging in the sweep today
- ACR Appropriateness Criteria for myelopathy updated for 2026
- Covers acute, chronic and vascular cord dysfunction
- Regulatory gaps for radiology are usually filled by appropriateness criteria, not approvals
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for radiology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free